Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

S. Venkatesan; R. Rosenthal; N. Kanu; N. McGranahan; J. Bartek; S. A. Quezada; J. Hare; R. S. Harris; C. Swanton

doi:10.1093/annonc/mdy003

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

S. Venkatesan, R. Rosenthal, N. Kanu, N. McGranahan, J. Bartek, S. A. Quezada, J. Hare, R. S. Harris, C. Swanton

Molecular Biology (BMBB)

Research output: Contribution to journal › Review article › peer-review

106 Scopus citations

Abstract

The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

Original language	English (US)
Pages (from-to)	563-572
Number of pages	10
Journal	Annals of Oncology
Volume	29
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdy003
State	Published - Mar 1 2018

Bibliographical note

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Keywords

APOBEC
Drug resistance
Human immunodeficiency virus
Immune escape
Intratumour heterogeneity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/annonc/mdy003

Find It

Find It at U of M Libraries

Cite this

@article{160796874abf4d1f9cb6adb256dbb9ca,

title = "Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution",

abstract = "The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.",

keywords = "APOBEC, Drug resistance, Human immunodeficiency virus, Immune escape, Intratumour heterogeneity",

author = "S. Venkatesan and R. Rosenthal and N. Kanu and N. McGranahan and J. Bartek and Quezada, {S. A.} and J. Hare and Harris, {R. S.} and C. Swanton",

year = "2018",

month = mar,

day = "1",

doi = "10.1093/annonc/mdy003",

language = "English (US)",

volume = "29",

pages = "563--572",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Perspective

T2 - APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

AU - Venkatesan, S.

AU - Rosenthal, R.

AU - Kanu, N.

AU - McGranahan, N.

AU - Bartek, J.

AU - Quezada, S. A.

AU - Hare, J.

AU - Harris, R. S.

AU - Swanton, C.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

AB - The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) mutational signature has only recently been detected in a multitude of cancers through next-generation sequencing. In contrast, APOBEC has been a focus of virology research for over a decade. Many lessons learnt regarding APOBEC within virology are likely to be applicable to cancer. In this review, we explore the parallels between the role of APOBEC enzymes in HIV and cancer evolution. We discuss data supporting the role of APOBEC mutagenesis in creating HIV genome heterogeneity, drug resistance, and immune escape variants. We hypothesize similar functions of APOBEC will also hold true in cancer.

KW - APOBEC

KW - Drug resistance

KW - Human immunodeficiency virus

KW - Immune escape

KW - Intratumour heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85046094021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046094021&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy003

DO - 10.1093/annonc/mdy003

M3 - Review article

C2 - 29324969

AN - SCOPUS:85046094021

SN - 0923-7534

VL - 29

SP - 563

EP - 572

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this